{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-24-000008","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.382916+00:00","generated_at":"2026-06-06T05:18:40.487189+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Curis Q4 2023 net loss $11.7M ($2.03/sh); cash $56.3M, clinical data from ASH shows CRs","bullets":["Net loss for Q4 2023 was $11.7M ($2.03/share) vs $11.3M ($2.35/share) in Q4 2022.","Revenue from Erivedge royalties was $2.7M for Q4 2023, flat YoY.","Cash & investments totaled $56.3M at Dec 31, 2023; company expects runway into 2025.","At ASH, emavusertib + ibrutinib achieved CR in 3 of 5 evaluable R/R PCNSL patients after BTKi failure.","Updated TakeAim Leukemia data expected H1 2024; lymphoma combo and triplet combo data in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-24-000008","json":"https://secwatch.observer/filing/0001108205-24-000008.json","markdown":"https://secwatch.observer/filing/0001108205-24-000008.md","text":"https://secwatch.observer/filing/0001108205-24-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/0001108205-24-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/cris-20240208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:18:40.487189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49321cf4673c32668df1ea27473ddeeac2212fa6","claim":"CURIS INC reported financial results for full year and quarter ended December 31, 2023.","evidence_excerpt":"On February 8, 2024, Curis, Inc. announced its financial results for the full year and quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000008/0001108205-24-000008-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year and quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}